Company Overview: Caymabay Therapeutics

Industry News

4 May

CymaBay to Report First Quarter 2017 Financial Results on Thursday, May 11

NEWARK, Calif., May 04, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan diseases with high unmet medical need, today announced that it will host a conference call and live audio webcast on Thursday, May 11th at 4:30...

Read more

13 Apr

CymaBay to Present Data from its Phase 2 Proof-of-Concept Study of Seladelpar in Patients With Primary Biliary Cholangitis at the EASL Liver Meeting 2017

NEWARK, Calif., April 13, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan diseases with high unmet medical need, today announced that data from its Phase 2 proof-of-concept study of seladelpar in patients with primary biliary cholangitis (PBC)...

Read more

30 Mar

CymaBay Therapeutics to Present at Two Investor Conferences in April

NEWARK, Calif., March 30, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company developing therapies for specialty and orphan diseases with high unmet medical need, today announced that management will provide a corporate overview at the H.C. Wainwright & Co. 1st Annual NASH Investor Conference, being...

Read more

9 Mar

CymaBay Therapeutics to Present at Two Investor Conferences in March

NEWARK, Calif., March 09, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, today announced that management will provide a corporate overview at the 29th Annual ROTH Conference, being held March 12-15, 2017...

Read more

7 Feb

CymaBay Therapeutics to Present at the 2017 BIO CEO & Investor Conference

NEWARK, Calif., Feb. 07, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, today announced that management will provide a corporate overview at the BIO CEO & Investor Conference, being held on February...

Read more

2 Feb

CymaBay Announces Pricing of Public Offering of Common Stock

NEWARK, Calif., Feb. 02, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan diseases with high unmet need, today announced the pricing of its previously announced underwritten public offering of 5,181,348 shares of its common stock at a...

Read more

5 Jan

CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate

NEWARK, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, today announced that it has successfully concluded its scientific advice discussions with the European Medicines Agency (EMA) on the Phase...

Read more

Page 1 of 712345...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address